James Talcott, MDSM

NPI: 1871580761
Total Payments
$5,446
2018 Payments
$3,123
Companies
2
Transactions
11

Payment Breakdown by Category

Consulting$2,350 (43.2%)
Research$2,323 (42.7%)
Travel$648.05 (11.9%)
Food & Beverage$124.97 (2.3%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $2,350 1 43.2%
Unspecified $2,323 2 42.7%
Travel and Lodging $648.05 5 11.9%
Food and Beverage $124.97 3 2.3%

Payments by Type

General
$3,123
9 transactions
Research
$2,323
2 transactions

Top Paying Companies

Company Total Records Latest Year
Eisai Inc. $3,123 9 $0 (2018)
NOVARTIS PHARMACEUTICALS CORPORATION $2,323 2 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2018 $3,123 9 Eisai Inc. ($3,123)
2017 $2,323 2 NOVARTIS PHARMACEUTICALS CORPORATION ($2,323)

All Payment Transactions

11 individual payment records from CMS Open Payments

Date Company Product Nature Form Amount Type
04/27/2018 Eisai Inc. Lenvima (Drug) Consulting Fee Cash or cash equivalent $2,350.00 General
Category: Oncology
04/27/2018 Eisai Inc. Lenvima (Drug) Travel and Lodging Cash or cash equivalent $524.61 General
Category: Oncology
04/27/2018 Eisai Inc. Lenvima (Drug) Travel and Lodging Cash or cash equivalent $67.34 General
Category: Oncology
04/27/2018 Eisai Inc. Lenvima (Drug) Food and Beverage Cash or cash equivalent $49.99 General
Category: Oncology
04/27/2018 Eisai Inc. Lenvima (Drug) Food and Beverage Cash or cash equivalent $49.99 General
Category: Oncology
04/27/2018 Eisai Inc. Lenvima (Drug) Food and Beverage Cash or cash equivalent $24.99 General
Category: Oncology
04/27/2018 Eisai Inc. Lenvima (Drug) Travel and Lodging Cash or cash equivalent $20.00 General
Category: Oncology
04/27/2018 Eisai Inc. Lenvima (Drug) Travel and Lodging Cash or cash equivalent $18.30 General
Category: Oncology
04/27/2018 Eisai Inc. Lenvima (Drug) Travel and Lodging Cash or cash equivalent $17.80 General
Category: Oncology
12/23/2017 NOVARTIS PHARMACEUTICALS CORPORATION FARYDAK (Drug) In-kind items and services $1,713.64 Research
Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: HEMATOLOGY
05/04/2017 NOVARTIS PHARMACEUTICALS CORPORATION FARYDAK (Drug) In-kind items and services $609.36 Research
Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: HEMATOLOGY

Research Studies & Clinical Trials

Study Name Company Amount Records
RESEARCH RELATED PUBLICATION SUPPORT NOVARTIS PHARMACEUTICALS CORPORATION $2,323 2

About James Talcott, MDSM

James Talcott, MDSM is a Medical Oncology healthcare provider based in New York, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1871580761.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, James Talcott, MDSM has received a total of $5,446 in payments from pharmaceutical and medical device companies, with $3,123 received in 2018. These payments were reported across 11 transactions from 2 companies. The most common payment nature is "Consulting Fee" ($2,350).

Practice Information

  • Specialty Medical Oncology
  • Location New York, NY
  • Active Since 10/05/2005
  • Last Updated 10/12/2015
  • Taxonomy Code 207RX0202X
  • Entity Type Individual
  • NPI Number 1871580761

Products in Payments

  • Lenvima (Drug) $3,123
  • FARYDAK (Drug) $2,323

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Medical Oncology Doctors in New York